Cost‐Effectiveness Analysis of Two Rituximab Retreatment Regimens for Longstanding Rheumatoid Arthritis

Publisher： John Wiley & Sons Inc

E-ISSN： 2151-4658|67|7|947-955

ISSN： 2151-464x

Source： ARTHRITIS CARE AND RESEARCH, Vol.67, Iss.7, 2015-07, pp. : 947-955

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug

By Kielhorn Adrian   Porter Duncan   Diamantopoulos Alexander   Lewis Gavin  

Current Medical Research and Opinion, Vol. 24, Iss. 9, 2008-09 ,pp. : 2639-2650

Informa Healthcare

Access to resources Recommend Favorite

Two Dosing Regimens of Certolizumab Pegol in Patients With Active Rheumatoid Arthritis

By  

ARTHRITIS CARE AND RESEARCH, Vol. 67, Iss. 2, 2015-02 ,pp. : 151-160

John Wiley & Sons Inc

Access to resources Recommend Favorite

Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced‐stage follicular lymphoma: A cost‐effectiveness analysis

By  

CANCER, Vol. 121, Iss. 15, 2015-08 ,pp. : 2637-2645

John Wiley & Sons Inc

Access to resources Recommend Favorite

A cost‐effectiveness analysis of two different repositioning strategies for the prevention of pressure ulcers

By  

JOURNAL OF ADVANCED NURSING, Vol. 71, Iss. 12, 2015-12 ,pp. : 2879-2885

John Wiley & Sons Inc

Access to resources Recommend Favorite

A French approach to cost-effectiveness analysis?

By Pouvourville Gérard  

The European Journal of Health Economics, Vol. 11, Iss. 6, 2010-12 ,pp. : 521-523

Springer Publishing Company

Access to resources Recommend Favorite